Protective Efficacy and Pulmonary Immune Response Following Subcutaneous and Intranasal BCG Administration in Mice.
Despite global coverage of intradermal BCG vaccination, tuberculosis remains one of the most prevalent infectious diseases in the world. Preclinical data have encouraged pulmonary tuberculosis vaccines as a promising strategy to prevent pulmonary disease, which is responsible for transmission. In this work, we describe the methodology used to demonstrate in the mouse model the benefits of intranasal BCG vaccination when compared to subcutaneous. Our data revealed greater protective efficacy following intranasal BCG administration. In addition, our results indicate that pulmonary vaccination triggers a higher immune response in lungs, including Th1 and Th17 responses, as well as an increase of immunoglobulin A (IgA) concentration in respiratory airways. Our data show correlation between protective efficacy and the presence of IL17-producing cells in lungs post-Mycobacterium tuberculosis challenge, suggesting a role for this cytokine in the protective response conferred by pulmonary vaccination. Finally, we detail the global workflow we have developed to study respiratory vaccination in the mouse model, which could be extrapolated to other tuberculosis vaccines, apart from BCG, targeting the mucosal response or other pulmonary routes of administration such as the intratracheal or aerosol.
Department of Microbiology, University of Zaragoza.
Santiago
S
Uranga
Department of Microbiology, University of Zaragoza.
Dessislava
D
Marinova
Department of Microbiology, University of Zaragoza.
Carlos
C
Martin
Department of Microbiology, University of Zaragoza; naguilo@unizar.es.
Nacho
N
Aguilo
D000281:Administration, Intranasal; D000818:Animals; D001500:BCG Vaccine; D020381:Interleukin-17; D051379:Mice; D009163:Mycobacterium bovis; D009169:Mycobacterium tuberculosis; D014376:Tuberculosis / Q000517:prevention & control; D014397:Tuberculosis, Pulmonary / Q000517:prevention & control*
D001500:BCG Vaccine; D020381:Interleukin-17
Am J Public Health Nations Health. 1958 Jul;48(7):844-53
13545447
Infect Immun. 2004 Jan;72(1):238-46
14688101
Mucosal Immunol. 2013 Sep;6(5):972-84
23299616
PLoS One. 2013 Oct 23;8(10):e78312
24194918
J Infect Dis. 2016 Mar 1;213(5):831-9
26494773
J Infect. 2006 Nov;53(5):350-6
16442629
J Immunol. 2009 Apr 15;182(8):4507-11
19342622
Nat Commun. 2015 Oct 13;6:8533
26460802
Clin Vaccine Immunol. 2014 Apr;21(4):594-7
24501340
Proc Natl Acad Sci U S A. 2002 Mar 19;99(6):3684-9
11891304
Tuber Lung Dis. 1993 Feb;74(1):38-46
8495019
Lancet Glob Health. 2015 Jan;3(1):e10-2
25539957
Clin Infect Dis. 2014 Feb;58(4):470-80
24336911
Adv Drug Deliv Rev. 2012 May 15;64(7):614-28
22119441
Nat Immunol. 2007 Apr;8(4):369-77
17351619
Nat Immunol. 2013 Apr;14(4):372-9
23475182
J Cereb Blood Flow Metab. 2015 Mar;35(3):371-81
25492117